SAS Output

21-OCT-2018 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9400 9383 0 0 0 0 0 02/28/2011 404 194
            9383 0 0 0 0 0      
 
    2 Y 2 Chemo and Endocrine Therapy 5000 2547 2 0 0 0 0 02/28/2011    
        3 Endocrine Therapy Alone   2536 1 0 0 0 0      
            5083 3 0 0 0 0      
 
  S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 1900 867 177 83 46 19 4 09/12/2013 441 212
        2 Blinded drug + Endocrine   866 166 75 33 7 2      
            1733 343 158 79 26 6      
 
  S1222-Brst,Fulv. +/- Ever. +/- Anastr. 1 T 1 Blinded treatment 840 12 0 0 0 0 0 05/15/2014 16 5
        2 Blinded treatment   12 0 0 0 0 0      
        3 Blinded treatment   13 0 0 0 0 0      
            37 0 0 0 0 0      
 
  S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 1 Y 1 Blinded Drug + Cisplatin 333 130 50 7 7 3 0 09/15/2016 266 132
        2 Blinded Drug + Cisplatin   138 59 17 17 8 3      
            268 109 24 24 11 3      
 
  S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1000 331 241 129 66 24 4 01/18/2017 465 209
            331 241 129 66 24 4      
 
    2 Y 2 Observation 1000 142 104 50 26 9 2 01/18/2017    
        3 MK-3475 (Pembrolizumab)   140 101 54 28 8 0      
            282 205 104 54 17 2      
 
Yes A011106-Breast, Neoadj, ALTERNATE study 1 E Total Registrations   77 27 21 13 3 2 04/29/2014   121
            77 27 21 13 3 2      
 
  E1Z11-Brst,Genetic Predictors of AIMSS 1 E Total Registrations   156 12 6 5 1 1 08/13/2013   34
            156 12 6 5 1 1      
 
  NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo 1 E Total Registrations   64 21 13 5 2 0 10/16/2015   223
            64 21 13 5 2 0      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 E Total Registrations   4 4 4 3 1 0 06/22/2018 11 11
            4 4 4 3 1 0      
 
No A011401-Breast, adj, Stage II/III HER2-, weight loss 1 E Total Registrations   187 110 57 27 9 2 10/05/2016   244
            187 110 57 27 9 2      
 
    2 E Total Registrations   169 103 52 26 9 1 10/05/2016    
            169 103 52 26 9 1      
 
  A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 1 E Total Registrations   56 38 24 6 4 1 03/20/2017 445 230
            56 38 24 6 4 1      
 
  A221405-Breast, ET interruption, Pregnancy Outcomes 1 E Total Registrations   13 9 4 2 0 0 05/08/2017 130 68
            13 9 4 2 0 0      
 
  B51-Breast, Regional Nodal XRT 1 E Total Registrations   32 12 7 3 0 0 06/13/2014   212
            32 12 7 3 0 0      
 
  B55-Brst, Adj Olaparib for BRCA,TNBC 1 E Total Registrations   67 22 10 3 0 0 12/15/2014 440 186
            67 22 10 3 0 0      
 
    2 E Total Registrations   32 12 8 4 0 0 12/15/2014    
            32 12 8 4 0 0      
 
  E2112-Brst,Adv,Exemestane+/-Entinostat 1 E Total Registrations   59 18 12 7 1 0 04/01/2015   162
            59 18 12 7 1 0      
 
  EA1131-Brst, TNBC, Post-op Chemo vs Obs 0 E Total Registrations   20 6 2 2 2 1 11/12/2015   131
            20 6 2 2 2 1      
 
    1 P Total Registrations   11 4 2 0 0 0 11/12/2015    
            11 4 2 0 0 0      
 
  EA1151-Brst, Tomosynthesis Mammographic Screening 1 E Total Registrations   209 209 154 65 25 6 01/30/2018 148 74
            209 209 154 65 25 6      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 E Total Registrations   1 0 0 0 0 0 09/22/2017 306 136
            1 0 0 0 0 0      
 

21-OCT-2018 6:10

BREAST Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1706 Breast, Inflammatory, RT +/- Olaparib 1 Randomization 12-Sep-18